Citations 2
Highlights From the Annual Meeting of the American Epilepsy Society 2022
Valencia, Ignacio , Alexander, Allyson , Andrade, Danielle M. , Arévalo, Miguel , Auer, Nancy A. , Bartoloméi, Fabrice , Becker, Danielle A. , Bernasconi, Andrea , Bernasconi, Neda , Bhatnagar, Shivani , Blumenfeld, Hal , Burdette, David E. , Conner, Kelly , Conway, Jeannine M. , Diaz-Arastia, Ramon, Drees, Cornelia , French, Jacqueline A. , Ganguly, Taneeta M. , Gotman, Jean , Guilfoyle, Shanna M., Gupta, Gita , Hentges, Katie, Huh, Linda , Kelley, Sarah A. , Vega‐Talbott, Maite La, Lam, Alice , Lowenstein, Daniel H. , Maturu, Sarita , McDonald, Carrie R. , McKee, Heather , Meador, Kimford J. , Michael, Elizabeth H., Mikati, Mohamad A. , Mitchell, James , Myers, Leah S. , Naritoku, Dean K., Neville, Kerri, Pavlova, Milena , Perry, Μ. Scott , Plueger, Madona, Pugh, Mary Jo , Quigg, Mark , Reddy, Shilpa B. , Reynolds, Tamara S. , Santana‐Gomez, Cesar , Schommer, Linsday, Shellhaas, Renée A. , Shrey, Daniel W. , Singh, Rani K. , Suleman, Saher, Templer, Jessica W. , Varadkar, Sophia , Velez‐Ruiz, Naymee , Velı́šková, Jana , Voskobiynyk, Yuliya , Wagner, Janelle L. , Wagnon, Jacy L. , Waller, Claire, Waller, Jill, Welborn, Michelle, Shellhaas, Renée A , Mikati, Mohamad A , Andrade, Danielle M , French, Jacqueline , Meador, Kimford J , Templer, Jessica W , McKee, Heather Ravvin , Ganguly, Taneeta Mindy , Burdette, David E , Valencia, Ignacio , Arevalo-Astrada, Miguel, Rubiños, Clio , Auer, Nancy, Bainbridge, Jacquelyn L. , Baxendale, Sallie , Berg, Anne T. , Bernhardt, Boris C. , Bhatnagar, Shivani, Blümcke, Ingmar , Buchanan, Gordon F. , Burneo, Jorge G. , Busch, Robyn M. , Chauvel, Patrick , Chin, Jeannie , Clifford, Lisa M. , Cook, Mark , Drees, Cornelia , Gelfand, Michael , Glauser, Tracy A. , Gleichgerrcht, Ezequiel L. , Goldman, Alica M. , González-Martínez, Jorge , Grinspan, Zachary M. , Hammer, Michael F. , Hartman, Adam L. , Hogan, R Edward , Hyslop, Ann , Jobst, Barbara C. , Josephson, Colin B. , Knupp, Kelly G. , Koepp, Matthias J. , Kothare, Sanjeev V. , Krook-Magnuson, Esther , Kwasa, Jasmine A. C. , Lee, Jong Woo , Mayor, Luis Carlos , McKhann, Guy M. , Mefford, Heather C. , Millichap, J Gordon , Noebels, Jeffrey L. , O’Brien, Terence J. , Oluigbo, Chima , Patel, Anup D. , Paz, Jeanne T. , Pennell, Page B. , Perucca, Piero , Pitkänen, Asla , Ryan, Christopher, Sajatovic, Martha , Schuele, Stephan , Sperling, Michael R. , Thom, Maria , Trinka, Eugen , Wang, Irène , Wirrell, Elaine
Epilepsy Currents | August 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available
With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.
Inequities in Therapy for Infantile Spasms: A Call to Action
Baumer, Fiona M. , Mytinger, John R. , Neville, Kerri, Abath, Christina Briscoe , Gutierrez, Camilo , Numis, Adam L. , Harini, Chellamani , He, Zihuai , Berg, Anne T. , Chu, Catherine J. , Gaillard, William D. , Pasupuleti, Archana, Samanta, Debopam , Singh, Rani K. , Singhal, Nilika S. , Wusthoff, Courtney J. , Yozawitz, Elissa , Shellhaas, Renée A. , Berg, Anne T , Chu, Catherine J , Baumer, Fiona M , Shellhaas, Renée A , Gaillard, William D , Yozawitz, Elissa G , Abath, Christina Briscoe , Wusthoff, Courtney J , Hussain, Shaun A. , Loddenkemper, Tobias , Wirrell, Elaine , Knupp, Kelly G. , Grinspan, Zachary M.
Annals of Neurology | April 7, 2022 | Volume: 92 | Issue: 1 | Pages: 32-44
ObjectiveThe aim of this study was to determine whether selection of treatment for children with infantile spasms (IS) varies by race/ethnicity.MethodsThe prospective US National Infantile Spasms Consortium database includes children with IS treated from 2012 to 2018. We examined the relationship between race/ethnicity and receipt of standard IS therapy (prednisolone, adrenocorticotropic hormone, vigabatrin), adjusting for demographic and clinical variables using logistic regression. Our primary outcome was treatment course, which considered therapy prescribed for the first and, when needed, the second IS treatment together.ResultsOf 555 children, 324 (58%) were non‐Hispanic white, 55 (10%) non‐Hispanic Black, 24 (4%) non‐Hispanic Asian, 80 (14%) Hispanic, and 72 (13%) other/unknown. Most (398, 72%) received a standard treatment course. Insurance type, geographic location, history of prematurity, prior seizures, developmental delay or regression, abnormal head circumference, hypsarrhythmia, and IS etiologies were associated with standard therapy. In adjusted models, non‐Hispanic Black children had lower odds of receiving a standard treatment course compared with non‐Hispanic white children (odds ratio [OR], 0.42; 95% confidence interval [CI], 0.20–0.89; p = 0.02). Adjusted models also showed that children with public (vs. private) insurance had lower odds of receiving standard therapy for treatment 1 (OR, 0.42; CI, 0.21–0.84; p = 0.01).InterpretationNon‐Hispanic Black children were more often treated with non‐standard IS therapies than non‐Hispanic white children. Likewise, children with public (vs. private) insurance were less likely to receive standard therapies. Investigating drivers of inequities, and understanding the impact of racism on treatment decisions, are critical next steps to improve care for patients with IS. ANN NEUROL 2022;92:32–44